Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2009 5
2010 3
2012 3
2013 3
2014 7
2015 10
2016 12
2017 15
2018 22
2019 10
2020 10
2021 6
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 34697138

101 results
Results by year
Filters applied: . Clear all
Page 1
A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.
Yamamoto J, Murata T, Tashiro Y, Higuchi T, Sugisawa N, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Hongo A, Nomura T, Saitoh W, Moriya T, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Anticancer Res. 2020 May;40(5):2509-2514. doi: 10.21873/anticanres.14221. Anticancer Res. 2020. PMID: 32366395
Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.
Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Shimoya K, Nomura T, Kurebayashi J, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Anticancer Res. 2020 May;40(5):2475-2479. doi: 10.21873/anticanres.14217. Anticancer Res. 2020. PMID: 32366391
Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.
Kawaguchi K, Miyake K, Zhao M, Kiyuna T, Igarashi K, Miyake M, Higuchi T, Oshiro H, Bouvet M, Unno M, Hoffman RM. Kawaguchi K, et al. Cell Cycle. 2018;17(16):2019-2026. doi: 10.1080/15384101.2018.1480223. Epub 2018 Sep 19. Cell Cycle. 2018. PMID: 29963961 Free PMC article.
Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Kawaguchi K, Igarashi K, Murakami T, Chmielowski B, Kiyuna T, Zhao M, Zhang Y, Singh A, Unno M, Nelson SD, Russell TA, Dry SM, Li Y, Eilber FC, Hoffman RM. Kawaguchi K, et al. Oncotarget. 2016 Dec 27;7(52):85929-85936. doi: 10.18632/oncotarget.13231. Oncotarget. 2016. PMID: 27835903 Free PMC article.
Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.
Kawaguchi K, Igarashi K, Murakami T, Kiyuna T, Zhao M, Zhang Y, Nelson SD, Russell TA, Dry SM, Singh AS, Chmielowski B, Li Y, Unno M, Eilber FC, Hoffman RM. Kawaguchi K, et al. Cell Cycle. 2017 Jul 3;16(13):1288-1294. doi: 10.1080/15384101.2017.1314420. Epub 2017 Jun 16. Cell Cycle. 2017. PMID: 28622068 Free PMC article.
Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP).
Miyake K, Kiyuna T, Miyake M, Zhao M, Wangsiricharoen S, Kawaguchi K, Zhang Z, Higuchi T, Razmjooei S, Li Y, Nelson SD, Russell T, Singh A, Murakami T, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Chawla SP, Eilber FC, Endo I, Hoffman RM. Miyake K, et al. Tissue Cell. 2018 Oct;54:144-149. doi: 10.1016/j.tice.2018.09.001. Epub 2018 Sep 14. Tissue Cell. 2018. PMID: 30309504
Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma.
Kiyuna T, Tome Y, Murakami T, Zhao M, Miyake K, Igarashi K, Kawaguchi K, Miyake M, Oshiro H, Higuchi T, Li Y, Dry SM, Nelson SD, Russell TA, Eckardt MA, Singh AS, Kanaya F, Eilber FC, Hoffman RM. Kiyuna T, et al. J Cell Biochem. 2018 Sep;119(9):7827-7833. doi: 10.1002/jcb.27183. Epub 2018 Jun 22. J Cell Biochem. 2018. PMID: 29932244 Free PMC article.
101 results